Blood Cancer News and Research

RSS

CAR-NK cells offer safer, more accessible treatment for lymphoma

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to patients.

15 Jan 2025

Computer model helps tailor CML treatment to individual patients

Which medicine is best when you are affected by cancer? This can vary from person to person. A new method can help people with a specific type of blood cancer get the best medicine for them.

9 Jan 2025

New research affirms clozapine safety with minimal blood cancer risk

An inter-departmental research team at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has conducted the world's first analytic real-world cohort study on the association of clozapine, a highly efficacious antipsychotic drug, with the incidence of blood cancer.

2 Jan 2025

Study uncovers how cancer builds molecular bridges to evade the immune system

"Build your enemy a golden bridge to retreat across" is a piece of advice offered by Sun Tzu in his ancient military treatise, The Art of War.

23 Dec 2024

New approach in fighting leukemia with double-modified natural killer cells

Various forms of blood cancer exist – all of which are grouped together under the term leukemia. One common form of leukemia is acute myeloid leukemia (AML), characterized by a degradation of early blood cell precursors, i.e. stem cells and the precursor cells that develop from them.

18 Dec 2024

Huntsman Cancer Institute joins innovative clinical trials program for blood cancers

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions in an innovative clinical trials program designed to match patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with a clinical trial specifically designed for the genetic signature of their disease.

17 Dec 2024

Scientists discover key protein that helps cancer cells evade CAR T cell therapy

Scientists at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, have collared a tricky culprit that helps cancer cells evade CAR T cell therapy.

17 Dec 2024

WashU Medicine receives $10.8 million grant to advance blood cancer research

Continuing its role as a leader in leukemia research, Washington University School of Medicine in St. Louis has been awarded a five-year, $10.8 million grant to further its exceptional programs in leukemia and other blood cancers.

16 Dec 2024

Scientists create blood test to enhance cancer treatment effectiveness

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

16 Dec 2024

Gene variant in Andean populations could help predict blood cancer treatment outcomes

Two researchers from Huntsman Cancer Institute at the University of Utah (the U) have discovered a gene variant found in high-altitude Andean populations that they believe could be a new biomarker for predicting the severity of diseases and treatment responses for certain types of blood cancer.

14 Dec 2024

Modified chemotherapy regimen for Hodgkin lymphoma reduces long-term side effects

A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that can result from treatment, according to researchers in Cambridge.

11 Dec 2024

High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following their initial treatment.

11 Dec 2024

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM).

10 Dec 2024

Novel drug combination shows promise for CLL treatment

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.

9 Dec 2024